Positive pleiotropic effects of HMG-CoA reduction inhibitor on vitiligo

Lipids in Health and Disease

Volumn 3, Issue , 2004, Pages

  Noël, Martin ^a   Gagné, Claude ^b   Bergeron, Jean ^b   Jobin, Jean ^a   Poirier, Paul ^a  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; METOPROLOL TARTRATE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PHYSICAL EXAMINATION; SKIN PIGMENTATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VITILIGO;

EID: 17944400958     PISSN: 1476511X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-511X-3-7     Document Type: Article

References (20)

1. Kemp EH, Waterman EA, Weetman AP: Autoimmune aspects of vitiligo. Autoimmunity 2001, 34:65-77.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
3. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-6.
4. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000, 101:207-13.
5. Palinski W, Tsimikas S: Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002, 13:1673-81.
6. Macaron C, Winter RJ, Traisman HS, Kahan BD, Lasser AE, Green OC: Vitiligo and juvenile diabetes mellitus. Arch Dermatol 1977, 113:1515-7.
7. Naughton GK, Eisinger M, Bystryn JC: Antibodies to normal human melanocytes in vitiligo. J Exp Med 1983, 158:246-51.
8. Smyth JR, McNeil M: Alopecia areata and universalis in the Smyth chicken model for spontaneous autoimmune vitiligo. J Investig Dermatol Symp Proc 1999, 4:211-5.
9. al-Fouzan A, al-Arbash M, Fouad F, Kaaba SA, Mousa MA, al-Harbi SA: Study of HLA class I/IL and T lymphocyte subsets in Kuwaiti vitiligo patients. Eur J Immunogenet 1995, 22:209-13.
10. Abdel-Naser MB, Ludwig WD, Gollnick H, Orfanos CE: Nonsegmental vitiligo: decrease of the CD45RA+ T-cell subset and evidence for peripheral T-cell activation. Int J Dermatol 1992, 31:321-6.
11. Badri AM, Todd PM, Garioch JJ, Gudgeon JE, Stewart DG, Goudie RB: An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 1993, 170:149-55.
12. Le Poole IC, Mutis T, van den Wijngaard RM, Westerhof W, Ottenhoff T, de Vries RR, Das PK: A novel, antigen-presenting function of melanocytes and its possible relationship to hypopigmentary disorders. J Immunol 1993, 151:7284-92.
13. Kawakami Y, Suzuki Y, Shofuda T, Kiniwa Y, Inozume T, Dan K, Sakurai T, Fujita T: T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. Pigment Cell Res 2000, 13 Suppl 8:163-9.
14. Kobashigawa JA:Statins as immunosuppressive agents. Liver Transpl 2001, 7:559-61.
15. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, Seidel D, Reichart B: Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997, 96:1398-402.
16. Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399-402.
17. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F: The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001, 131:41-6.
18. Maggard MA, Ke B, Wang T, Kaldas F, Seu P, Busuttil RW, Imagawa DK: Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation 1998, 65:149-55.
19. Meiser BM, Wenke K, Thiery J, Wolf S, Devens C, Seidel D, Hammer C, Billingham ME, Reichart B: Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 1993, 25:2077-9.
20. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-7.